LiveGood Methylene Blue Nootropic Strips

⚡ Quick Answer

LiveGood Methylene Blue Nootropic Strips are dissolving oral strips with methylene blue as the active ingredient. Methylene blue is FDA-approved as a prescription drug for treating methemoglobinemia — it is not FDA-approved as a dietary supplement or nootropic. As a potent MAO inhibitor, it can cause life-threatening serotonin syndrome when combined with SSRIs, SNRIs, MAOIs, and certain other medications. Anyone taking antidepressants, psychiatric medications, or opioids must not use this product without explicit approval from their prescriber.

⚠️ Critical Safety Facts — Read Before Buying

• FDA Drug Safety Communication (October 2011): The FDA warned that combining methylene blue with SSRIs, SNRIs, MAOIs, and other serotonergic medications can cause serious, sometimes fatal serotonin syndrome. This is an active FDA safety warning.
• Methylene blue is a potent MAO-A inhibitor. This is not a minor interaction note — it is the same mechanism that makes MAOIs (monoamine oxidase inhibitors) dangerous to combine with antidepressants. Methylene blue adds this risk.
• SSRIs contraindicated: The FDA prescribing information for Lexapro (escitalopram) and other SSRIs explicitly lists IV methylene blue as contraindicated. This includes fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), escitalopram (Lexapro), and others.
• G6PD deficiency is an absolute contraindication. Methylene blue can cause severe hemolytic anemia in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency — confirmed in FDA prescribing information for Provayblue.
• Blue-green discoloration of urine is expected and benign — a documented, normal effect confirmed in clinical literature. Temporary mouth discoloration can also occur.

📌 Key Facts at a Glance

• Methylene blue is an FDA-approved prescription drug (brand name Provayblue) for treating methemoglobinemia — a serious blood disorder where hemoglobin cannot carry oxygen. This is its only FDA-authorized medical use.
• As a dietary supplement, methylene blue is in a regulatory gray area. It is not FDA-approved as a supplement or nootropic. Using it as a supplement is an off-label application without clinical endorsement.
• Serotonin syndrome can develop rapidly and be fatal within 24 hours. It causes mental status changes, muscle twitching, excessive sweating, shivering, diarrhea, coordination problems, and fever. Anyone combining methylene blue with serotonergic medications is at risk.
• The strip format is the product’s main practical advantage — no capsule to swallow, pre-portioned, easy to carry. The dissolving film delivers methylene blue orally without measuring.
• Low-dose oral methylene blue has been studied for cognitive effects in early-stage research — animal models and small human studies. Evidence at supplemental doses is preliminary. The Phase 3 Alzheimer’s trials by TauRx (using a methylene blue derivative) did not show overall benefit.
• This product is for adults only. Not appropriate for people under 18, pregnant, nursing, or managing neurological conditions without professional guidance.

Product: LiveGood Methylene Blue Nootropic Strips

Format: Dissolving oral strips

Main ingredient: Methylene blue

Best fit: Adults comparing a convenient nootropic-style strip for a focus-support routine, who have confirmed no medication conflicts with their prescriber

Check first if: You take any medication — especially antidepressants, psychiatric medications, opioids — or are pregnant, nursing, have G6PD deficiency, blood, kidney, liver, heart, blood pressure, mood, or neurological concerns, or are under 18.

What the Research Shows on Methylene Blue

🏛️ What Health Authorities Say

• FDA (October 2011 Drug Safety Communication): warned of “serious central nervous system reactions, including serotonin syndrome” that are “potentially life-threatening or fatal” when methylene blue is combined with serotonergic psychiatric medications.
• FDA Provayblue prescribing information: lists G6PD deficiency as a contraindication (severe hemolytic anemia risk) and explicitly requires avoiding co-use with SSRIs, SNRIs, MAOIs, and opioids.
• StatPearls / NIH NCBI: confirms serotonin syndrome risk, G6PD contraindication, and adverse effects profile including headache, nausea, myoclonus, and cardiovascular effects. Blue urine documented as expected and benign.
• Anesthesia Patient Safety Foundation (APSF): identifies methylene blue as a “potent MAO inhibitor” and documents the serotonin toxicity risk clearly in clinical practice guidance.
• Regulatory status: Methylene blue is a prescription drug for methemoglobinemia. Its use as a dietary supplement is not FDA-approved and lacks the clinical evidence base that approved medical applications have.

If you take antidepressants, opioids, or psychiatric medications — do not use this product without explicit approval from your prescriber. This is a serious, documented drug interaction, not a precautionary note.

You take antidepressants, psychiatric medications, or opioids

This is the most critical safety check. SSRIs, SNRIs, tricyclics, MAOIs, and opioids are all documented interactions with methylene blue that can cause life-threatening serotonin syndrome. Do not use without explicit approval from your prescriber.

You have G6PD deficiency or blood-related concerns

Methylene blue is contraindicated in G6PD deficiency. Risk of severe hemolytic anemia.

You take any other medication

Ask a pharmacist or healthcare professional before adding methylene blue to your routine.

You have liver, kidney, heart, blood pressure, neurological, or mood-related concerns

This ingredient needs extra caution if you manage a health condition.

You are pregnant or nursing

Do not use unless your healthcare professional says it is appropriate for your situation.

You are under 18

This product is positioned for adults only.

Sources & References

1. FDA. Drug Safety Communication: Serious CNS Reactions Possible when Methylene Blue is Given to Patients Taking Certain Psychiatric Medications. October 20, 2011. fda.gov
2. FDA. Provayblue (methylene blue) Prescribing Information. accessdata.fda.gov
3. Schep LJ, et al. Methylene Blue. StatPearls. NCBI Bookshelf. Updated 2024. ncbi.nlm.nih.gov
4. Anesthesia Patient Safety Foundation. Methylene Blue and the Risk of Serotonin Toxicity. apsf.org
5. Ramsay RR, et al. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A confirms a theoretical prediction. British Journal of Pharmacology. 2007;152(6):946–951. pmc.ncbi.nlm.nih.gov
6. MedlinePlus. Methylene Blue Injection. medlineplus.gov